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Recent epidemiological and immunological studies provide evidence for an association between Epstein–Barr virus infection and
multiple sclerosis, suggesting a role of Epstein–Barr virus infection in disease induction and pathogenesis. A key question in this
context is whether Epstein–Barr virus-infected B lymphocytes are present within the central nervous system and the lesions of
patients with multiple sclerosis. Previous studies on this topic provided highly controversial results, showing Epstein–Barr virus
reactivity in B cells in the vast majority of multiple sclerosis cases and lesions, or only exceptional Epstein–Barr virus-positive B
cells in rare cases. In an attempt to explain the reasons for these divergent results, a workshop was organized under the
umbrella of the European Union FP6 NeuroproMiSe project, the outcome of which is presented here. This report summarizes
the current knowledge of Epstein–Barr virus biology and shows that Epstein–Barr virus infection is highly complex. There are still
major controversies, how to unequivocally identify Epstein–Barr virus infection in pathological tissues, particularly in situations
other than Epstein–Barr virus-driven lymphomas or acute Epstein–Barr virus infections. It further highlights that unequivocal
proof of Epstein–Barr virus infection in multiple sclerosis lesions is still lacking, due to issues related to the sensitivity and
speciﬁcity of the detection methods.
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Multiple sclerosis is a chronic inﬂammatory disease of the CNS that
leads to demyelination and a variable degree of neurodegenera-
tion (Lassmann et al., 2007; Frischer et al., 2009). However, little
is currently known regarding the mechanisms that drive the chron-
ic inﬂammatory process. Autoimmunity against CNS antigens is
one possible explanation and this concept is, in part, supported
by experimental data and by the detection of autoimmune reac-
tions in some patients with multiple sclerosis (Hohlfeld and
Wekerle, 2004). Another possible explanation could be that a per-
sistent infection in the CNS or elsewhere in the body triggers an
immunopathological response either directly or through auto-
immunity. One of the potential candidates for a persistent infec-
tion, which has received increasing attention during the last years,
is the Epstein–Barr virus (EBV) (Lu ¨nemann and Mu ¨nz, 2009;
Salvetti et al., 2009; Ascherio and Munger, 2010; Maghzi et al.,
2010). Epidemiological evidence strongly supports an association
of EBV infection with multiple sclerosis (Handel et al., 2010; Levin
et al., 2010) and higher levels of EBV antibodies [in particular
those speciﬁc for Epstein–Barr nuclear antigen 1 (EBNA1)] have
been consistently found in the serum of patients with multiple
sclerosis compared with control individuals (Ascherio and
Munger, 2010). Evidence is also growing that patients with mul-
tiple sclerosis have a higher EBV-speciﬁc cellular immune response,
both at the level of CD4 and CD8 T cells (Ho ¨llsberg et al., 2003;
Lu ¨nemann et al., 2006, 2008; Jilek et al., 2008; Jaquiery et al.,
2010). While enhanced immune reactivity to EBV in multiple
sclerosis is indicative of altered virus–host interactions, it is not
clear yet whether EBV has a direct role in multiple sclerosis devel-
opment or acts as an activator of the underlying disease process
(Salvetti et al., 2009; Pender, 2011). EBV employs numerous
mechanisms to perturb the immune system, including molecular
mimicry, induction of heat shock proteins and superantigens, and
immortalization of autoreactive B cells. In favour of molecular
mimicry, earlier studies showed that a myelin basic protein-speciﬁc
T cell clone derived from a patient with multiple sclerosis cross-
reacts with an EBV DNA polymerase peptide (Ufret-Vincenty
et al., 1998; Lang et al., 2002). EBV-speciﬁc T cells cross-reacting
with myelin basic protein were found in the CSF of a patient
with multiple sclerosis (Holmoy et al., 2004) and it has been
shown that EBNA1-speciﬁc CD4
+ T cells from some patients with
multiple sclerosis partially cross-react with myelin antigens
(Lu ¨nemann et al., 2008). Alternatively or in addition, chronic per-
sistence of EBV-infected cells in the CNS, possibly associated
with lytic reactivation, could directly drive an immunopatho-
logical response causing tissue injury in the patients, a scenario
supported by the ﬁnding that EBV-speciﬁc CD8 T cells accumulate
in the CSF of patients with multiple sclerosis (Jaquiery et al.,
2010). Given the importance of elucidating the link between
altered immune reactivity to EBV and brain pathology in mul-
tiple sclerosis, the topic of this report is to critically review the
available evidence for the presence of EBV in the multiple sclerosis
brain.
EBV infects a very high percentage of humans and persists in a
latent form in the B cells of the host (Evans, 1989;
Thorley-Lawson, 2001). Persistent intrathecal B cell activation is
the hallmark of multiple sclerosis (Obermeier et al., 2008;
Owens et al., 2009; Lovato et al., 2011) and B cells and plasma
cells are part of the inﬂammatory inﬁltrates in multiple sclerosis
white matter lesions and meninges (Esiri, 1977; Prineas and
Wright, 1978; Seraﬁni et al., 2004, 2007; Magliozzi et al.,
2007, 2010; Frischer et al., 2009; Lovato et al., 2011). In patients
with multiple sclerosis with progressive disease and a very severe
inﬂammatory and neurodegenerative pathology, large B cell ag-
gregates have been described in the meninges. These structures
show some features of lymphoid B cell follicles with germinal
centres (Seraﬁni et al., 2004, 2007; Aloisi and Pujol-Borrell,
2006; Magliozzi et al., 2007, 2010). Given the consistency of
the serological data and the increasing literature on altered T cell
responses to EBV in patients with multiple sclerosis, it has
been hypothesized that, in the presence of a susceptible genetic
background, EBV infection may not be controlled properly,
that circulating infected B cells might enter the CNS and that
intracerebral activation of the infection might sustain the chronic
inﬂammatory process leading to multiple sclerosis (Pender, 2003,
2011).
Support for this concept came from recent studies (Seraﬁni
et al., 2007, 2010) which—using immunohistochemical, in situ
hybridization and reverse transcriptase-polymerase chain reaction
techniques in post-mortem brain tissue—found evidence for dys-
regulated EBV infection in the multiple sclerosis brain. These au-
thors described a high frequency of EBV-infected cells among B
cells inﬁltrating white matter lesions and meninges in multiple
sclerosis, but not in other inﬂammatory diseases of the CNS
(Seraﬁni et al., 2007). EBV was detected in 95% of the tissue
samples analysed (21 out of 22) and a highly signiﬁcant correl-
ation was found between EBV-infected cells and the total number
of CD20
+ B cells. The data also suggested an interaction between
cytotoxic CD8
+ T cells and EBV-infected B cells (Seraﬁni et al.,
2007). However, subsequent studies using similar technologies
were unable to detect EBV in the brain tissue of the same and
other cohorts of patients with multiple sclerosis (Willis et al., 2009;
Peferoen et al., 2010; Sargsyan et al., 2010; Torkildsen et al.,
2010). These divergent results may have several explanations.
Although basically similar technologies have been used, several
methodological differences may lead to differences in the sensitiv-
ity of the assays. This may be a particular issue when dealing with
autopsy brain samples with suboptimal tissue preservation and
subjected to different processing procedures. In addition, there is
a wide spectrum of pathological features of multiple sclerosis
lesions, depending upon the type and severity of the disease as
well as the stage of the lesions (Lucchinetti et al., 2000; Lassmann
et al., 2007).
In an attempt to identify the reasons underlying these discrep-
ant results, a 2-day workshop promoted by the European Union
FP6 Integrated Project ‘NeuroproMiSe’ was organized at the
Centre for Brain Research of the Medical University of Vienna in
July 2010. By bringing together all research groups that have ad-
dressed the issue of EBV infection in the multiple sclerosis brain,
the workshop aimed to provide an update on EBV biology, discuss
the individual experiences regarding the search of EBV in patho-
logical tissues and deﬁne future research directions.
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Basic features of the biology of
Epstein–Barr virus infection
The currently favoured model of the EBV life cycle is schematically
depicted in Fig. 1 and Table 1. Primary EBV infection occurs via
the oral route leading to infection of submucosal B cells in
oropharyngeal lymphoid tissues (Hutt-Fletcher, 2007). Upon
infection, EBV transforms these cells into actively growing
immunoglobulin-producing B cell blasts through a limited
number of essential viral gene products [EBNA1–6, latent mem-
brane proteins 1, 2a and 2b (LMP1, 2a, 2b) and non-coding small
RNAs, EBER1, 2 and several microRNAs] (Middeldorp et al., 2003;
Young and Rickinson, 2004; Swaminathan, 2008; Chaganti et al.,
2009). This type of EBV infection (latency-III or growth pro-
gramme) is also seen in vitro in lymphoblastoid cell lines and
does not usually involve virus production (Thorley-Lawson, 2001).
Table 1 Latency types of EBV-infected cells and their gene expression repertoire
Latency type Gene repertoire Associated diseases
Type -0/-1 (true latency) EBER1, 2 and BARTs (microRNA),
EBNA1
Peripheral blood (memory) B cells, Burkitt’s lymphoma, dividing
EBV
+ B cells
Type -2 (default) EBER1, 2 and BARTs (microRNA),
EBNA1, LMP1, LMP2A, 2Band
BARF1
a
Hodgkin disease, B cell non-Hodgkin lymphoma, T-/NK-cell
non-Hodgkin lymphoma and nasopharyngeal carcinoma
a
Type -3 (growth) EBER1, 2 and BARTs/BHRF1
(microRNA) EBNA1, EBNA2,
EBNA3A, 3B, 3C, EBNA-LP,
LMP1, LMP2A, 2B
Lymphoblastoid cell lines, post-transplant lymphoproliferative disorders,
AIDS-related lymphomas and infectious mononucleosis
Others EBER1, 2 and BARTs (microRNA)
EBNA1, LMP2a and BARF1
a
Gastric carcinoma
a
a BARF1 is only expressed in epithelial malignancies (e.g. nasopharyngeal carcinoma and gastric carcinoma).
Genes indicated in bold highlight those important for stage-speciﬁc differentiation.
Figure 1 Schematic presentation of EBV infection and persistence in vivo. EA = early antigen; IE = immediate early; VCA = viral capsid
antigen.
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can comprise nearly 60% of all T cells, and are subsequently large-
ly eliminated (Hislop et al., 2007, 2010). The cytokines produced
during this process cause the clinical syndrome of infectious mono-
nucleosis. Subsequently, EBV establishes a lifelong persistent infec-
tion of memory B cells, a process accompanied by epigenetic
silencing of most viral coding genes, but leaving expression of
non-coding small RNAs unaffected (Thorley-Lawson and Allday,
2008; Paschos et al., 2009). By shutting down the expression of
most EBV-encoded antigens, EBV-infected memory B cells become
invisible to the immune system and circulate permanently in the
blood in low but stable numbers (1/10
5 B cells) for the lifetime
of the host (Latency-0/-I or true latency programme; Khan et al.,
1996). When proliferating, these B cells may switch on EBNA1,
which is crucial for maintenance of the viral episome in dividing
cells (Hochberg et al., 2004). T cell control of EBV remains at high
levels for life (1% of all T cells are permanently reactive to EBV
antigens) and provides an effective control against re-emergence
of EBV-driven B-blasts.
How EBV enters the memory B cell pool is not entirely clear.
Three possibilities are discussed, that may not be mutually exclu-
sive: EBV may directly infect memory B cells during primary infec-
tion (Kurth et al., 2000; Chaganti et al., 2009). Alternatively, EBV
may infect naı ¨ve B cells, which differentiate into memory B cells by
passage through germinal centre reactions exploiting physiological
B cell differentiation pathways (Niedobitek et al., 1992; Khan,
2006). Finally, EBV may itself drive naı ¨ve B cell differentiation to-
wards memory B cells by substituting signals that are normally
provided to antigen-selected B cells in germinal centres through
CD40 and immunoglobulin (Ig) receptor by constitutive signalling
through its proteins LMP1 and LMP2, respectively. In support of
this concept, EBV
+ B cells expressing activation-induced cytidine
deaminase (AID), a protein required for immunoglobulin class
switch as well as for somatic hypermutation, have been detected
outside germinal centres in infectious mononucleosis tonsils
(Tobollik et al., 2006). Intriguingly, in this scenario, it would
become possible for B cells expressing autoreactive antibodies to
enter the memory B cell compartment.
Circulating EBV-infected memory B cells preferentially home to
lymphoid tissues in the head and neck region but may be detect-
able anywhere in the organism where B cells accumulate. Upon
re-entry into lymphoid tissues, they may express the LMPs and
EBNA1, and undergo limited activation and proliferation mimicking
the germinal centre process (Latency-II or default programme)
(Laichalk et al., 2002; Roughan et al., 2010). In this setting, po-
tentially transforming viral gene products are allowed to be ex-
pressed together and to drive a limited expansion of EBV-infected
B cells (Fig. 2; Middeldorp et al., 2003). LMP2a may provide
additional survival signals and prevent B cell differentiation into
plasma cells. Importantly, no EBNA2-6 re-expression is found in
these cells, reﬂecting tight epigenetic promoter silencing. This pro-
cess of EBV latent reactivation into the default programme may be
triggered particularly by local inﬂammatory cytokines (Kis et al.,
2006, 2010), but is kept under tight control by EBV-speciﬁc T cells
in the healthy host (Hislop et al., 2005). Thus, latently
EBV-infected B cells may be attracted to sites of inﬂammation,
e.g. driven by TNF, IL6, CXCL13, to become locally activated
into proliferation. Interestingly, subtle physiological inﬂuences,
Figure 2 EBV gene expression mimicking the migration and germinal centre selection process. miRNA = microRNA.
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latency causing temporary enhanced viral gene expression and
triggering aberrant immune responses (Glaser et al., 2005).
Pathological conditions involving aberrant B cell triggering, such
as severe chronic inﬂammation or infection, with temporary
immune imbalance may be responsible for altering the balance
between EBV and its host and set the stage for more serious
complications (Thorley-Lawson, 2001; Middeldorp et al., 2003;
Young and Rickinson, 2004). By providing an array of survival
signals and manipulating host gene regulation, EBV inﬂuences
and overrides a variety of molecular control pathways that are
crucial for normal B cell function. These inﬂuences are exerted
through a limited number of EBV gene products (Fig. 2), which
provide advantage to EBV and B cell survival, but carry the inher-
ent risk of oncogenic host cell transformation or allow the survival
of normally forbidden (e.g. autoimmune) clones.
When triggered to become plasma cells, EBV
+ B cells express
the full coding content of the viral genome to allow virus replica-
tion, which is accompanied by virus-driven anti-apoptotic signal-
ling and immune evasion strategies ensuring cell survival for the
production of viral progeny (Laichalk and Thorley-Lawson, 2005;
Ressing et al., 2008). Viral replication is initiated by the ZEBRA
protein (also known as BZLF1 or Zta), a nuclear transcription
factor driving viral and host gene expression and mediating eva-
sion from innate immune responses (Miller et al., 2007). The
ZEBRA protein is under scrutiny by T cells limiting the number
and lifespan of virus producing cells (Hislop et al., 2007). Upon
ZEBRA expression, a cascade of lytic cycle gene expression is
induced involving distinct sets of interdependent immediate early
genes (transcription factors and regulators), early genes (including
enzymes involved in nucleotide metabolism, viral DNA replication,
immune evasion, apoptosis resistance, etc.) and late genes (virus
structural proteins and immune evasins). Besides full virus replica-
tion, EBV may also express a limited ‘abortive’ form of lytic infec-
tion, where gene expression is limited to Zta and a few early viral
proteins. Interestingly, the switch to lytic replication is accompa-
nied by a stop in the expression of small EBER RNAs, whereas
other latent products (i.e. LMP1) are upregulated (Gilligan et al.,
1990; Webster-Cyriaque et al., 2000). It is unclear if virus repli-
cation in plasma cells results in the liberation of infectious virus
particles in quantities sufﬁcient to allow spread of the virus to
other individuals. It is considered likely that additional ampliﬁcation
of virus production in oropharyngeal epithelial cells is required
(Hadinoto et al., 2009).
Recently, it was found that viral latency products (i.e. LMP1,
LMP2, small RNAs) can be released from EBV-infected cells in
exosomes, and can manipulate cells in the microenvironment
and even systemically support inﬂammation and immune escape
(Dukers et al., 2000; Flanagan et al., 2003; Houali et al., 2007;
Iwakiri et al., 2009; Pegtel et al., 2010). This may lead to the
accumulation of virus-related products in non-infected cells
(Pegtel et al., 2010). If this phenomenon interferes with diagnostic
techniques used for the in situ detection of EBV is presently
unknown.
Disruption of the host–virus immune balance may lead to aber-
rant behaviour of EBV-infected cells resulting in several distinct
benign and malignant disease syndromes. Although infrequent,
neurological disease has been associated with acute and chronic
EBV infection with detectable virus in the CNS, and it is well es-
tablished that EBV-positive diffuse large B cell lymphomas may
develop in the brains of HIV-infected individuals. Therefore,
there may be a link between EBV and neurological disease,
whether this is acute, chronic or malignant.
In summary, current evidence suggests that EBV has hijacked B
cell biology for its own survival through a limited number of viral
gene products, while remaining largely invisible to the immune
system. In healthy individuals, EBV persists in memory B cells
that preferentially home to lymphoid tissues in the head and
neck region, but which can also travel to areas of inﬂammation.
Here EBV carrying B cells may become activated and can multiply
upon temporary or local loss of immune control. When activated,
EBV
+ B cells may secrete cytokines and viral components thus
possibly contributing to inﬂammation as well as immune escape.
These events may take place in inﬂammatory regions of the CNS
of patients with multiple sclerosis.
Subcellular localization of different
Epstein–Barr virus encoded RNAs
or proteins and their detection in
tissue sections
In order to assess the possible contribution of EBV to any neoplas-
tic or non-neoplastic disease, in situ detection of viral genomes or
gene products is of pivotal importance. For example, EBV gen-
omes may be detectable in DNA extracts from human tumours
by polymerase chain reaction suggesting an EBV association.
In situ analysis of such cases, however, may reveal occasional
EBV-positive lymphocytes admixed with the EBV-negative
tumour cells as the source of the polymerase chain reaction signal.
In general, EBV gene products have a deﬁned subcellular local-
ization relating to their function and can be detected equally well
in (ﬁxed) cell lines in vitro as well as in (tumour) tissues ex vivo.
The basic features of EBV biology, as described above, should be
considered when applying deﬁned EBV-speciﬁc reagents to condi-
tions with suspected EBV involvement, aiming to understand or
explain possible EBV-driven pathogenic events. Therefore, appro-
priate negative (e.g. reactive lymph node) and positive tissues
(EBV
+ Hodgkin lymphoma, nasopharyngeal carcinoma or infec-
tious mononucleosis tonsil) should always be processed in parallel
with the tissue to be examined, in addition to negative reagent
controls.
In situ detection of EBV infection should follow a step-wise,
hierarchical procedure. First, the presence of EBV infection must
be established. Ideally, this is done by EBV DNA in situ hybridiza-
tion since this technique detects viral genomes and is independent
of viral gene expression. Sensitive methods, suitable for the detec-
tion of single viral copies, have been described in certain model
systems, although this technique may require the use of radiola-
belled probes (Niedobitek and Herbst, 2006). In practice, EBV
DNA in situ hybridization has been successfully used to detect
EBV in certain tumours. However, it is not sufﬁciently sensitive
or robust to deﬁnitely exclude the presence of EBV in case of
negative results.
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expressed in all known forms of EBV latency in vivo and in vitro
and serve as gold standard for detecting latent EBV infection in
situ (Khan et al., 1992; Hamilton-Dutoit and Pallesen, 1994), are
considered to reside exclusively or at least predominantly in the
nucleus. Cytoplasmic staining is, therefore, generally considered as
non-speciﬁc (Gulley et al., 2002; Gulley and Tang, 2008). An ex-
ception to this rule is cells undergoing mitosis, which may show
diffuse cytoplasmic labelling as a consequence of the loss of the
nuclear membrane. Recent studies have, however, shown a func-
tion for EBERs in the cytoplasm, and secretion of EBERs via
cytoplasmic vesicles or as La-EBER protein–RNA complexes may
be physiological, thus weakening this strict diagnostic criterion
(Iwakiri et al., 2009). However, generally RNA in situ hybridiza-
tion reveals pure nuclear staining in EBV-associated tumours
(Fig. 3B). EBERs are estimated to be present at 41 million
copies per cell and should be easily detected when RNA quality
is preserved. The advantage of EBER staining by RNA in situ
hybridization is that even sporadic EBV
+ B cells can be clearly
visualized in a pathological tissue. However, detection of EBERs
requires well-controlled staining procedures in order to avoid false
positive (over staining) or negative results (due to RNA
Figure 3 EBER peptide nucleic acid staining pitfalls: comparison of detection by alkaline phosphatase and horseradish peroxidise. EBER
expression was studied in an inﬂammatory epithelial lesion using the identical EBER peptide nucleic acid (PNA) probe labelled with FITC
(DAKO Kit) applied under identical standardized tissue preparation and hybridization conditions (as described in the DAKO EBER PNA
procedure) with subsequent detection (A) according to the manufacturer’s protocol with standard rabbit anti-FITC labelled with alkaline
phosphatase and BCIP/NBT developing reagent, or (B) using a modiﬁed protocol involving rabbit anti-FITC and Streptavidin–horseradish
peroxidase (DAKO) detection and diaminobenzidene as developing reagent. Although both methods allowed detection of EBER-positive
nuclei (A1 and B1) as appropriate sign of EBV presence in the tissue (black arrows), the alkaline phosphatase detection generally gave a
problematic background staining especially in the cytoplasm of non-EBV-infected lymphoid cells (open arrow in A2 and A3). These cells
may be plasma cells as judged by the enlarged cytoplasm. Such cytoplasmic staining is regularly observed in inﬁltrating lymphoid cells with
plasma cell appearance in otherwise EBV negative inﬂammatory tissues. By using the alternative protocol (B), no such cytoplasmic staining
was revealed and generally a very sharp nuclear boundary was produced (B1, B2), with occasionally less precise lining (single cell in B1),
suggesting of EBER leakage into the cytoplasm. This should be considered when interpreting published data on EBV involvement in
multiple sclerosis with commercial detection kits (Seraﬁni et al., 2007, 2010; Peferoen et al., 2010).
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bridization, precautions should be taken to preserve tissue and
RNA integrity (proper tissue ﬁxation and use of RNase-free cutting
knife and buffers, preferably in a clean cross-ﬂow cabinet), and
RNA integrity should be checked in each sample by performing
RNA in situ hybridization for a house-keeping gene, such as the
U6 cellular RNA (Niedobitek et al., 2000). Several (commercial)
methods may be valid (Gulley et al., 2002, 2008). The frequently
used alkaline phosphatase-based detection of RNA in situ
hybridization signals with BCIP/NBT as substrate/chromogen
may provide very strong signals, but is prone to non-speciﬁc
background staining, which may make interpretation difﬁcult
(Fig. 3A).
The EBNA1 protein, which is also expressed in all forms of EBV
latency, is largely conﬁned to the nucleus as revealed by immu-
nohistochemistry (Fig. 4A–C). Multiple anti-EBNA1 reagents are
available, some of which have potential false reactivity due to
epitope sharing. Thus, one rat monoclonal antibody, designated
2B4, has also been reported to produce nuclear staining of some
EBV-negative cells in the original publications (Grasser et al., 1994;
Murray et al., 1996). Nevertheless, this antibody has been repeat-
edly used for the detection of EBV infection in human tumours
leading to reports describing the detection of EBV in unexpected
situations, e.g. breast and prostate cancer (Bonnet et al., 1999;
Grinstein et al., 2002; Preciado et al., 2005). More recently, it was
shown that this antibody, like the 1H4 antibody, cross-reacts with
Figure 4 Detection of EBV antigen expression in human tissues. A variety of EBV antigens can be detected by a characteristic staining
pattern using deﬁned monoclonal antibody reagents. EBNA1 expression (detected by mouse monoclonal antibody OT1x) is characterized
by a (sometimes punctuated) nuclear staining as revealed in gastric cancer (A), Hodgkin’s lymphoma (B) and B cell lymphoproliferative
lesions (C). LMP1 expression (detected by mouse monoclonal antibody OT21C) is characterized by a homogeneous cytoplasmic and
membraneous staining as revealed in nasopharyngeal carcinoma (D), Hodgkin’s lymphoma (E) and blastoid cells in post-transplant
lymphoproliferative disease (F, LMP1 stained in blue). Note that the parallel expression of nuclear EBNA2 (detected by rat monoclonal
antibody R3) in smaller cells in the same lesion (F, EBNA2 stained in brown), suggesting a heterogeneous proliferative process (Brink et al.,
1997). Zebra protein expression (detected by the mouse monoclonal antibody BZ1) is strictly nuclear as revealed by staining of
post-transplant lymphoproliferative disease (G) or oral hairy leukoplakia (H). The structural capsid protein VCA-p18 can be abundantly
detected in oral hairy leukoplakia as revealed by rat monoclonal antibody OT15E (I).
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usual results observed by some groups (Murray et al., 2003).
Other antibodies, while more speciﬁc, often produce only weak
staining. Thus, EBNA1 immunohistochemistry, on its own, has to
be considered unreliable for the detection of EBV infection.
Nevertheless, once EBV infection has been established by EBER
speciﬁc in situ hybridization, immunohistochemistry is useful for
characterizing the type of EBV latency and to identify cells enter-
ing into the lytic cycle of EBV infection. Antibodies suitable for the
detection of EBNA2 and LMP1 have been widely used to study
EBV latency in various settings (Fig. 4D and F; Herbst et al., 1991;
Niedobitek et al., 1992, 1995, 1997). The immunohistochemical
detection of LMP2A expression is also possible but is technically
more challenging and is also prone to false positive staining, e.g.
of mantle zone lymphocytes (Niedobitek et al., 1997; Heussinger
et al., 2004).
The switch from latent to lytic infection is triggered by the BZLF1
protein, also known as ZEBRA or Zta, and immunohistochemistry
using a BZLF1-speciﬁc monoclonal antibody has proved useful for
the in situ detection of lytic EBV infection (Herrmann et al., 2002;
Frangou et al., 2005). ZEBRA protein can be readily detected by
the BZ1 monoclonal antibody that is commercially available and
gives a strong nuclear signal in cells undergoing lytic infection
(Fig. 4G and H). Additional reagents directed against early or
late viral proteins are useful to establish to what extent virus rep-
lication is complete or remains abortive.
For detection of full lytic EBV replication, it is necessary to dem-
onstrate additional early and late viral gene products. Preferred
early antigens comprise the BMRF1 (pol-accessory protein) and
BALF2 (major DNA binding protein) products (Zeng et al., 1997;
Zhang et al., 1998; Herrmann et al., 2002; Frangou et al., 2005).
An additional early marker is the viral bcl2 homologue BHRF1
(Nicholls et al., 2001). The detection of true late antigens associat-
ing with productive replication is possible by using monoclonal
antibodies to viral capsid components [BFRF3 (VCA-18), BdRF1
(VCA-p40), BcLF1 (VCA-p160)] or the gp350/220 envelope pro-
tein (BLLF1) (Zhang et al., 1998; Hermann et al., 2002; Frangou
et al., 2005). The detection of lytic gene expression can be most
clearly demonstrated in AIDS-associated oral hairy leukoplakia
(Fig. 3I), which is the only pathological condition associated with
full EBV replication (Webster-Cyriaque et al., 2000). Most of the
early and lytic markers have a nuclear and cytoplasmic localization,
whereas the gp350/220 has a cytoplasmic membrane localization.
Virion structural antigens tend to spread into the micro-
environment (Fig. 3I). Although only few studies have directly
addressed co-expression of EBV proteins in situ, it is generally
believed that full lytic replication is a continuous process once
triggered beyond the stage of early antigen expression. Some evi-
dence suggest that cells may undergo abortive infection when
expressing the BZLF1 (Zebra) protein only, but this largely relies
on in vitro data.
During uncomplicated virus persistence, the in situ detection of
EBV latent genes and even more so of viral lytic gene expression
has proven extremely difﬁcult (Frangou et al., 2005; Hudnall
et al., 2005; Chen and Hudnall, 2006). However under various
pathological conditions, EBV gene expression can be detected in
deﬁned tissues as outlined above. In subclinical situations, such as
stress and inﬂammation, EBV reactivation occurs, which may tem-
porarily lead to increased EBV production, as reﬂected by elevated
EBV DNA levels in blood and saliva as well as elevated antibody
responses (Glaser et al., 2005; Gulley, 2008).
In summary, on the basis of currently available evidence, it is
recommended that investigators use EBER-speciﬁc in situ hybrid-
ization for the detection of EBV infection followed by immunohis-
tochemistry to identify the type of virus latency and the switch
from latency to lytic infection.
In recent years, multiple approaches using polymerase chain
reaction technology have been used to detect EBV genomes
(DNA load) in tissue ﬂuids, in particular blood, plasma, saliva
and CSF. In general, during uncomplicated virus persistence, EBV
DNA can easily be detected in saliva, but is rare in internal
compartments (Stevens et al., 2002; Gulley, 2008; Hadinoto
et al., 2009). In fact, the blood compartment contains usually
510 infected B cells per millilitre.
In general, in the immunocompetent host, ﬂuctuations in anti-
EBV immune responses reﬂect the host–virus relationship, being
aberrant in (sub)clinical situations involving EBV (Glaser et al.,
2005; de Sanjose et al., 2007; Stevens et al., 2007).
Interestingly, although not detailed here, there is a consistency
in studies reporting abnormalities in the immune response to a
particular EBV protein EBNA1, but not to other EBV proteins or
other viruses, in patients with multiple sclerosis (Lu ¨nemann et al.,
2008; Sundstrom et al., 2009; Jafari et al., 2010). This appears to
involve both T cell and B cell responses to deﬁned regions
(epitopes) in the middle to C-terminus of EBNA1, and is linked
to an increased risk of developing multiple sclerosis. Importantly, it
has been reported that certain EBNA1-speciﬁc CD4
+ T cell clones
cross-react with myelin to produce interferon gamma upon stimu-
lation (Lu ¨nemann et al., 2008). How and if this anti-EBNA1
immune response reﬂects or contributes to inﬂammation in
multiple sclerosis remains to be determined, but aberrant EBNA1
reactivity has been suggested as surrogate marker for multiple
sclerosis risk (Lu ¨nemann and Munz, 2009; Ascherio and Munger,
2010, Simon et al., 2010).
Presence of Epstein–Barr virus
in the multiple sclerosis brain
Polymerase chain reaction-based
evidence
Several groups have attempted to identify EBV infection in the
multiple sclerosis brain by polymerase chain reaction methodology.
Summarizing the experience of all laboratories, there is good
agreement that with polymerase chain reaction technology it is
easily possible to detect infection in EBV
+ tumour control tissue
or in lymphoblastoid cell lines. However, EBV infection in whole
multiple sclerosis brain sections or single cells isolated from
the CSF was very rarely detected (Morre ´ et al., 2001; Willis
et al., 2009; Peferoen et al., 2010; Sargsyan et al., 2010). A
positive result was obtained only by using pre-ampliﬁcation poly-
merase chain reaction techniques (Sargsyan et al., 2010; Seraﬁni
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cell inﬁltrates using laser capture microdissection (Seraﬁni et al.,
2010).
Willis et al. (2009) performed real-time polymerase chain reac-
tion for the detection of genomic EBV as well as real-time poly-
merase chain reaction for the abundant EBV-encoded RNA. A ﬁrst
set of 17 brain samples from ﬁve cases with multiple sclerosis,
which contained white matter lesions, were completely negative
with both techniques despite a robust signal for CD20 messenger
RNA and the presence of CD20
+ B cells, conﬁrmed by immuno-
histochemistry. In a second set, the investigation focused on
12 tissue samples, three of which contained B cell aggregates in
the brain parenchyma and four of which contained a loose B cell
inﬁltrate in the meninges. EBV RNA was seen in two out of 12
cases and one of these also contained EBV DNA. The conclusion
was that, if present at all, only very few EBV
+ cells were con-
tained in the samples. Similarly, a negative result was obtained
with real-time polymerase chain reaction by Torkildsen et al.
(2010) for EBNA1, EBNA2, LMP1 and LMP2 messenger RNA.
Morre ´ et al. (2001) and Sargsyan et al. (2010) did not detect
EBER1 transcripts in single B lymphocytes and plasma cells derived
from multiple sclerosis CSF, nor EBV-speciﬁc transcripts (EBER1,
EBNA2, LMP1 and BFRF-1) in 15 multiple sclerosis lesions from
14 patients, ﬁve of them being reported previously by Seraﬁni
et al. (2007) to have a high load of EBV-infected B cells.
However, in a second study Sargsyan et al. (2010) evaluated an
additional group of parafﬁn-embedded multiple sclerosis plaques
and positive and negative control lymphoma tissue pre-screened
for EBV DNA by nested real-time polymerase chain reaction and
conﬁrmed the presence of EBV in rare multiple sclerosis tissue
samples. In contrast to EBV
+ lymphoma tissue, EBER1-positive
multiple sclerosis plaque contained no additional EBV-speciﬁc tran-
scripts such as EBNA2, LMP1 and BFRF-1, consistent with latency
stage 0 of EBV infection. In a recent report, Seraﬁni et al. (2010)
were unable to detect LMP2A and EBNA1 transcripts by quanti-
tative real-time polymerase chain reaction in multiple sclerosis
whole brain sections. However, selective pre-ampliﬁcation of com-
plementary DNAs allowed detection of a low polymerase chain
reaction signal for LMP2A and EBNA1 in two and three of four
brain samples, respectively. Moreover, these authors showed high
levels of transcripts for LMP2A and EBNA1 relative to the
house-keeping gene GAPDH and to the B cell-associated gene
CD19 in all inﬂammatory cell inﬁltrates that were isolated from
the meninges and white matter lesions (both active and chronic
active) with laser capture microdissection (Seraﬁni et al., 2010).
According to Seraﬁni et al. (2010), these results are consistent
with the observation that, even in the most inﬁltrated mul-
tiple sclerosis brain samples, total and EBV-infected B cells repre-
sent only a very minor proportion of the total population of CNS
resident and inﬂammatory cells and are highly concentrated in
very tiny areas, like the perivascular spaces of post-capillary
venules and the leptomeningeal space. Besides aspects related to
B cell frequency and localization, the possibility that the levels
of viral transcripts in EBV-infected B cells surviving in a chronic-
ally inﬂamed environment are much lower than in EBV
+ tumour
cells could help explain why selection of B cell-enriched areas and
increased polymerase chain reaction sensitivity are so crucial for
successful detection of EBV in the multiple sclerosis brain.
Evidence based on in situ hybridization
for EBER and immunocytochemistry
The largest discrepancies between the groups related to the mor-
phological detection of EBV-infected cells in tissue sections.
Seraﬁni et al. (2007, 2010) report that a very high percentage
of CNS inﬁltrating B cells are positive for EBER by in situ hybrid-
ization and for the EBV latent proteins LMP1 and LMP2A by
immunohistochemistry. This abundant positive staining is in con-
trast to the completely negative ﬁndings obtained by Willis et al.
(2009) and H. Lassmann (unpublished results). Largely negative
results have also been obtained by the Dutch group (Peferoen
et al., 2010). In the latter study, 4632 tissue blocks from
94 patients with multiple sclerosis were screened for the presence
of B cells. From the B cell-rich group (16 cases) comprising
60 blocks, 1–2 blocks from each patient (28 in total) were ana-
lysed for the presence of EBV using EBER in situ hybridization. In
addition, eight blocks from other cases with multiple sclerosis in
the Dutch cohort in which B cells were observed in the meninges
were also screened. The only positive signal for EBER was seen in a
few cells within a single lymphocyte-rich region in a single block of
a single multiple sclerosis case. On the contrary, U. Meier,
J. Tzartos and G. Khan (London) discussed unpublished results,
reporting the presence of EBER-expressing cells in preselected
IFN- over-expressing active multiple sclerosis lesions, but surpris-
ingly also in acute stroke lesions. In contrast to the above-
mentioned studies, these authors used a non-commercial set of
EBER1 and -2 probes in an in situ hybridization protocol, which
they have established to be capable of detecting single
EBV-infected lymphocytes (Khan et al., 1992). A problem of this
particular study is that the morphology of cells with nuclear EBER
signal within the lesions was not always typical for B cells,
particularly in stroke lesions and double staining for EBER
expression in B cells has not been performed.
Similar discrepancies exist regarding immunocytochemical detec-
tion of EBV antigens in multiple sclerosis brains and lesions. There
was full agreement that the antibodies used for detection of EBV
antigens in multiple sclerosis lesions are suitable to detect staining
of EBV-infected cells in infected control tissue. In multiple sclerosis
brain tissue, however, the results show major discrepancies.
Several groups report completely negative results with antibodies
against latent antigens (LMP1 or EBNA2; Willis et al., 2009;
Peferoen et al., 2010; Torkildsen et al., 2010) with the exception
of expression of antigens related to lytic infection in a single lesion
of a single case (Peferoen et al., 2010). In contrast, Seraﬁni et al.
(2010) observed that 40–80% of all CD20
+ B cells in the multiple
sclerosis brain expressed LMP2A on their membrane. Most B cells
also showed staining using an LMP1-speciﬁc reagent, while
EBNA2
+ cells were rarely observed, suggesting expression of the
default programme. The same group also found that a substantial
proportion of plasma cells in the inﬂamed meninges, ectopic B
cell follicles and perivascular cuffs of active white matter lesions
(30–55%), but not in chronic active lesions, also expressed BFRF1,
2780 | Brain 2011: 134; 2772–2786 H. Lassmann et al.an antigen associated with the early phase of lytic infection
(Seraﬁni et al., 2007). Such abundance of plasma cells is not con-
ﬁrmed by others and the speciﬁcity of the anti-BFRF1 antibody is
not conﬁrmed (J. Middeldorp, unpublished results). The Seraﬁni
et al. (2007) study further describes widespread expression of
LMP1 and BFRF1 in B cell-rich perivascular cuffs of two patients
who died from fulminate acute multiple sclerosis. However,
this early study did not analyse the expression lytic switch
ZEBRA protein, for which a well-reactive reagent (BZ-1 antibody)
is available. More recently, the presence of EBV lytically infected
plasma cells in the most inﬂamed multiple sclerosis brains was
conﬁrmed using the BZ-1 antibody speciﬁc for Zebra (B. Seraﬁni,
unpublished results). However, the prevalence of EBV-infected B
cells and their frequent (re-)activation into default or lytic cycle in
speciﬁc reactive B cell-rich regions of the brain in patients with
multiple sclerosis, as described by the Seraﬁni et al. (2007, 2010),
remains to be conﬁrmed.
Interpretation of the polymerase chain
reaction and morphological data
The profound discrepancies between the results of the different
groups are currently difﬁcult to explain. Thus, most of the discus-
sion during the meeting was devoted to this topic. No consensus,
acceptable to all participants, could be reached.
The view, shared by the majority (H.L., G.N., J.M.M., K.O.C.,
J.B., W.B., C.S., S.A., P.v.V., U.C.M.) was that EBV infection in the
multiple sclerosis brain is, when present at all, restricted to a very
low number of B cells. The majority group also agreed that evi-
dence from inﬂammatory control brain tissue is at present insufﬁ-
cient to judge whether it is multiple sclerosis speciﬁc or just reﬂects
an accumulation of EBV-infected B cells in B cell-rich inﬂammatory
human brain lesions as a bystander phenomenon. Conversely,
based on the immunohistochemical and EBER in situ hybridization
data obtained in 12 cases with other inﬂammatory neurological
diseases including primary vasculitis, viral encephalitis, mycotic
and bacterial meningoencephalitis and one case with neuromyelitis
optica, (Seraﬁni et al., 2007, 2010 and unpublished results), these
authors concluded that intracerebral enrichment in EBV-infected B
cells is characteristic of and speciﬁc for the multiple sclerosis brain
only.
The discrepancies between the results of the different studies
were felt by the majority to be mainly due to technical issues and
interpretation of immunocytochemistry and in situ hybridization,
but not due to differences in case/lesion selection or the preser-
vation of brain tissue samples. These conclusions are based on
the following considerations: First, evidence from attempts to
detect EBV infection in the multiple sclerosis brains by (real time)
polymerase chain reaction suggests that EBV-related DNA or RNA
in multiple sclerosis brains and lesions are rare and most likely
restricted to a small number of cells. Secondly, the chance of its
detection appears to increase with enrichment of B cells within the
tissue sample and, thus, is highest when B cell inﬁltrates are select-
ively isolated by laser microdissection. This, however, requires
independent conﬁrmation. Whether EBV-infected B cells within
the multiple sclerosis brain are disease-speciﬁc or just reﬂect
B cell inﬁltration and activation in the inﬂamed brain remains
unclear, since proper inﬂammatory controls with comparable
B cell inﬁltration and activation in the brain (such specimens
are very rare) have so far not been included in the polymer-
ase chain reaction studies. Altogether, this suggests that highly
sensitive techniques have to be used to obtain positive results
with polymerase chain reaction technology. This notion apparently
contrasts with the reported high percentage of EBV-infected B
cells as detected by EBER in situ hybridization and immunohisto-
chemistry in cases with multiple sclerosis (Seraﬁni et al., 2007,
2010).
Quantitative studies on the composition of inﬂammatory inﬁl-
trates in multiple sclerosis agree that the numbers of B lympho-
cytes within the lesions are highly variable between cases. Thus,
one potential explanation for the divergent results could be that
the pathological spectrum of the cases, in particular regarding B
cell inﬁltrates, differed between the studies. This, however, is not
likely for several reasons. First, all studies took care to include
cases with substantial B cell inﬁltrates and larger B cell aggregates
and this is well documented in the respective publications.
Secondly, several groups (Rome, Boston/Go ¨ttingen, Amsterdam)
have used in part tissue blocks from the same patients derived
from a single tissue bank (UK Multiple Sclerosis Tissue Bank).
EBER in situ hybridization has even been performed on consecu-
tive frozen or parafﬁn sections from the same blocks with diver-
gent results between different centres (Rome, Amsterdam and
Vienna). Providing the same cases from the same tissue bank ex-
cludes differences in pre-mortem conditions, autolysis time, ﬁx-
ation and handling of the tissue blocks may explain the
divergent results, although it does not exclude differences in
tissue processing and storage in the individual laboratories.
Thus, technical issues related to the sensitivity of EBV detection
in tissue sections became the centre of interest. One aspect,
which seems to be important, is the type of material is used.
The positive ﬁndings have been obtained in Rome by using to a
large extent cryopreserved tissue ﬁxed with formaldehyde (either
prior or after freezing and cutting) but also a smaller number of
parafﬁn samples obtained from Vienna and Amsterdam. In the
negative studies by Willis et al. (2009), Sargsyan et al. (2010)
and Peferoen et al. (2010), both frozen- and parafﬁn-embedded
tissue has been used in parallel. Although the EBER in situ hybrid-
ization as well as the immunocytochemistry for EBV in principle
works in both types of tissue sections, higher sensitivity results
may be reached in frozen sections, but possibly at the expense
of a higher chance of non-speciﬁc reactions. Yet, it is unlikely that
this explains the divergent results, since in the studies by Willis
et al. (2009) and Peferoen et al. (2010), tissue material from
cases with multiple sclerosis that were rated positive in the study
by Seraﬁni et al. (2007), were obtained from the UK Multiple
Sclerosis Tissue Bank under identical conditions of tissue
preservation.
Thus, issues related to the speciﬁcity of the in situ hybridization
and immunohistochemical reactions have to be considered, which
are of particular relevance when dealing with plasma cells, with
their very high cytoplasmic content of RNA and immunoglobulin.
In situ hybridization for EBER has been performed in the studies by
Seraﬁni et al. (2007) with the methodology that was used by
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detailed inspection of the original Fig. 2 of this article (Seraﬁni
et al., 2007) at high magniﬁcation reveals that the majority of
EBER-positive cells show an unstained central portion, surrounded
by a darkly stained halo. Such a staining pattern is highly suggest-
ive of cytoplasmic reactivity. As discussed above, this subcellular
distribution of reactivity is unexpected for the EBERs in latently
EBV-infected cells. EBERs may be exported from the nuclei into
cytoplasmic exosomes (Pegtel et al., 2010), but this in general is
rare and quantitatively minor compared with nuclear EBER expres-
sion in B lymphocytes. In diagnostic pathology exclusively cyto-
plasmic EBER reactivity is considered non-speciﬁc, unrelated to
EBV infection. An exception to this are cells undergoing mitosis,
where breakdown of nuclear membrane leads to leaking of EBERs
into the cytoplasm. Also the immunohistochemical results were
not regarded as fully convincing due to a rather low signal to
background ratio (see Seraﬁni et al., 2010, Fig. 1 in the respective
study). In addition, the very high number of cells, expressing early
lytic EBV antigens in relation to those expressing latent antigens or
just B cell markers, was seen as rather unusual for EBV-infected
tissue, since in other situations, such as infectious mononucleosis
or post-transplant lymphoproliferative disorders, the proportion of
EBV-infected lymphocytes entering into the lytic cycle is extremely
small. Finally, one antibody speciﬁc for BFRF1, which showed a
highly positive result for the group based in Rome, was also eval-
uated by the Amsterdam group and revealed negative results in
their multiple sclerosis samples and false positive results in control
lymphoid tissue.
A fundamentally different interpretation was provided by the
group from Rome (F.A., B.S.) as discussed in detail by Aloisi
et al. (2010). In particular, the cytoplasmic localization of EBER,
which was not observed in any of the brain samples from cases
with other inﬂammatory neurological diseases examined or in con-
trol lymphoid tissues (Seraﬁni et al., 2007, 2010 and unpublished
results), is not interpreted in such a dogmatic manner and as a
necessarily non-speciﬁc ﬁnding. The coexistence of EBER
+ cells
with either a nuclear or cytoplasmic signal in the multiple sclerosis
brain is rather seen as a feature that may be unique to multiple
sclerosis and could be related to the survival and expansion of
non-tumour EBV-infected cells in a chronically inﬂamed environ-
ment, with possible extracellular spread of EBER molecules, a con-
dition that is fundamentally different from EBV-associated tumours
or primary EBV infection. A careful re-analysis of EBV gene ex-
pression proﬁles in inﬂammatory conditions may thus be needed.
Concerning the immunohistochemical ﬁndings, it may be neces-
sary to more carefully consider the biology of EBV infection and its
gene expression proﬁles in latency and lytic cycle as described
above. The use of different protocols and of a non-overlapping
panel of antibodies could account for the discrepancies observed
and stresses the need for further standardization. It should also be
considered that most protocols used to reveal EBV antigens in
tumour biopsies need to be adapted for frozen or ﬁxed frozen
autopsy brain tissue. Finally, the distribution of EBV markers in
the multiple sclerosis brain is compatible with a predominantly
latent viral infection while reactivation events in plasma cells are
restricted to active lesions and ectopic B cell follicles, namely to
areas that can be found only after an extensive screening of
multiple sclerosis brain samples (Aloisi et al., 2010). These areas
may not have been included sufﬁciently in the brain samples ana-
lysed by the other groups.
Conclusion
Currently the evidence for the presence of EBV-infected cells in
the brain of patients with multiple sclerosis remains controversial.
Experience ranges widely between different groups, one seeing an
expression in the vast majority of B cells in all inﬂamed brain
samples (Rome) while the others ﬁnding no or only exceptional
EBV-positive cells in very few patients (most groups present). After
an extensive and detailed discussion of all the results, it was felt
that independent conﬁrmation of the presence of a multiple
sclerosis-associated EBV infection in the CNS had so far not
been achieved by any of the groups participating at the workshop.
However, during the preparation of this manuscript Dr Luca Muzio
at San Raffaele Scientiﬁc Institute in Milan analysed, in a blind
manner, seven different ﬁxed frozen brain samples of the UK mul-
tiple sclerosis cohort using a highly sensitive, radioactive in situ
hybridization technique (Muzio et al., 2005; Centonze et al.,
2009) with EBER1- and EBER2-speciﬁc probes (Niedobitek et al.,
1991) that differ from those used by Seraﬁni et al. (2007). The
data obtained by Muzio were reported to conﬁrm the presence of
EBV-infected cells in multiple sclerosis lesions and to provide a
picture that overlaps, in terms of localization and frequency of
EBV-infected cells, to that obtained by Seraﬁni et al. in adjacent
brain sections using a non-radioactive EBER in situ hybridization
protocol (L. Muzio and B. Seraﬁni, unpublished results). However,
the original slides have not been available for assessment.
Therefore, while acknowledging that these results may be rele-
vant, the working group is not able to provide a consensus opinion
on this unpublished set of experiments.
There was agreement that an additional attempt should be
made focusing on brain tissue samples that are regarded by the
group in Rome as those with the highest level of EBV infection.
This material should be sent to other groups for independent
conﬁrmation on all three levels (in situ hybridization, immunocyto-
chemistry and polymerase chain reaction) using technical proto-
cols on which agreement has been reached beforehand. These
additional experiments may clarify whether or not there is a
massive EBV infection in the CNS-inﬁltrating B cell population in
patients with multiple sclerosis, as described by Seraﬁni et al.
(2007, 2010).
In case the presence of EBV-infected B cells in the majority of
multiple sclerosis brains should be conﬁrmed, investigations in
other chronic inﬂammatory brain diseases will become of critical
importance. Particularly interesting will be to study patients with
chronic B cell activation and plasma cell inﬁltration in the CNS,
associated with intrathecal immunoglobulin synthesis. This may
help to exclude that EBV activation within the tissue is just a
non-speciﬁc response to B cell activation in inﬂammatory brain
lesions. Given the widely conﬁrmed epidemiological and serologic-
al evidence linking EBV to multiple sclerosis and the growing lit-
erature on altered T cell responses to EBV in multiple sclerosis, it is
mandatory that further work is done to better understand how
2782 | Brain 2011: 134; 2772–2786 H. Lassmann et al.altered virus–host interactions contribute to multiple sclerosis
pathogenesis.
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